<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04036253</url>
  </required_header>
  <id_info>
    <org_study_id>BIOS-HPFS-0115</org_study_id>
    <nct_id>NCT04036253</nct_id>
  </id_info>
  <brief_title>Study of HEMAX PFS Versus EPREX/ ERYPO® in Predialysis Chronic Kidney Disease</brief_title>
  <official_title>A Randomized, Comparative Study of HEMAX PFS® Versus EPREX/ ERYPO® in the Treatment of Anemia With Epoetin Alfa in Patients With Predialysis Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio Sidus SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio Sidus SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III, multicenter, randomized, open, controlled clinical trial. A study designed as
      phase III, in 120 patients with chronic renal failure in the pre-dialysis stage, evaluate
      efficacy and safety of Hemax PFS® (PFS: prefilled syringes) vs the innovator erythropoietin
      alfa product (Eprex®).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Anticipated">January 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Evaluation through the increase of Hemoglobin levels</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Evaluate the efficacy of treatment with erythropoietin alfa through increased levels of hemoglobin from baseline value to the mean value of the 8 to 12 weeks of treatment, comparing patients treated with HEMAX® PFS versus EPREX/ ERYPO®.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events and Adverse Reactions (safety and tolerability) at week 12</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Evaluate the safety through the incidence of adverse events and adverse reactions after 12 and 24 weeks of treatment, comparing patients treated with HEMAX® PFS versus those treated with EPREX/ ERYPO®.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events and Adverse Reactions (safety and tolerability) at week 24</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Evaluate the safety through the incidence of adverse events and adverse reactions after 12 and 24 weeks of treatment, comparing patients treated with HEMAX® PFS versus those treated with EPREX/ ERYPO®.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders patients</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Evaluate the efficacy of treatment with erythropoietin alfa through the percentage of responder patients (increase of Hb ≥ 1g/ dl) after 12 weeks of treatment, comparing patients treated with HEMAX® PFS versus those treated with EPREX/ ERYPO®.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients that required any Transfusion</measure>
    <time_frame>12 weeks of treatment</time_frame>
    <description>Evaluate the percentage of transfusional requirement after 12 weeks of treatment, comparing patients treated with HEMAX PFS versus those treated with EPREX/ ERYPO®.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hemoglobin level at week 12 of treatment</measure>
    <time_frame>Intragroup efficacy until week 12</time_frame>
    <description>Evaluate the efficacy between arms (HEMAX® PFS and EPREX/ ERYPO®) of treatment with erythropoietin alfa through the change in the level of hemoglobin from baseline in every visit until the week 12 visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the efficacy between arms 24 weeks: week doses in the titration</measure>
    <time_frame>Intragroup efficacy until week 24</time_frame>
    <description>Evaluate the efficacy between arms (HEMAX® PFS and EPREX/ ERYPO®) of the change from the twice - a - week doses in the titration phase to a weekly dose in the maintenance phase through the changes in the hemoglobin levels from week 12 to weeks 16, 20 and 24 of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti-drug antibodies (immunogenicity)</measure>
    <time_frame>12 and 24 weeks of treatment</time_frame>
    <description>An anti-erythropoietin alfa antibody determination will be performed to evaluate treatment immunogenicity at week 12 and 24 visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Hepcidin</measure>
    <time_frame>24 weeks of treatment</time_frame>
    <description>Hepcidin will be analyzed by ELISA at baseline, week 12 and 24 in order to evaluate the treatment response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Anemia of Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Eprex/Erypo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receive EPREX/ ERYPO® subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.
There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hemax PFS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receive HEMAX® PFS subcutaneously with an initial dose of 29 IU/ kg twice a week (2000 IU twice a week for 70 kg of weight), to be titrated according to the scheme that is summarized below.
There will be a follow - up of patients with visits to the site every two weeks during the first 12 weeks of dose titration that will be followed by 12 additional weeks of dose maintenance with visits every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Erythropoietin alfa</intervention_name>
    <description>Prefilled syringes of erythropoietin</description>
    <arm_group_label>Eprex/Erypo</arm_group_label>
    <arm_group_label>Hemax PFS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years

          -  Patients with pre-dialysis chronic renal failure (CRF) defined by a glomerular
             filtration rate (calculated with the Modification of Diet in Renal Disease Study
             formula) ≥15 ml/ min and &lt;60 ml/ min, by 1.73 m2

          -  Anemic patients that should be treated and levels of hemoglobin &lt;10.5 g/dl and ≥ 7.5
             g/dl.

          -  Patients that have the will and capacity to sign a written inform consent.

          -  Post-menopause women for at least 2 years, or sterile by surgery for at least 6
             months. Women of childbearing age must have a negative pregnancy test at baseline and
             be willing to get an adequate method of contraception.

        Exclusion Criteria:

          -  Patients that are planned to be on dialysis or have a renal transplant in the
             following 6 months.

          -  Transferrin iron Saturation &lt; 20%.

          -  Etiology of renal failure (as secondary to autoimmune diseases) that, to the judge to
             the physician, can affect the normal development of the protocol.

          -  Active bleeding or history of hemorrhage that have led to a significative decrease of
             hematocrit in the last 30 days.

          -  Non-controlled hypertension (≥160 mm Hg of systolic pressure and/or ≥100 mm Hg of
             diastolic pressure with anti-hypertensive treatment).

          -  Anemia caused by any other cause than renal disease.

          -  Having a transfusion in the last 3 months before basal visit or during screening.

          -  Treatment with an erythropoiesis stimulant in the last 3 months before basal visit or
             screening.

          -  Increase risk of thromboembolic disease: history of arterial thromboembolia (stroke,
             transient ischemic attack, Acute coronary syndrome, etc.) in the last 6 months or
             venous in the last 12 months before screening; surgery in the last month before
             screening; prolong immobilization or orthopedic surgery programmed in the following 6
             months or any other condition that to the judge of the investigator can increase the
             risk of thromboembolism.

          -  Hematological disease or myelodysplastic syndrome or history of hematological neoplasm
             or solid tumor in the last 5 years.

          -  History of congestive heart failure

          -  Pregnancy or breast feeding

          -  Refuse to participate in the protocol or any medical condition, that in the
             investigator opinion, is significant to prevent the participant from being included in
             the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roberto Diez</last_name>
    <phone>+541149098000</phone>
    <email>r.diez@biosidus.com.ar</email>
  </overall_contact>
  <location>
    <facility>
      <name>CEMEDIC</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Arias</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEREHA</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Elbert</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIMEL</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Lopez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIPREC (Centro de Investigación y Prevención Cardiovascular)</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcelo de Rosa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>GEMA Consultorio</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonardo Sivak</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Argerich</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merdeces Grizzo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Británico de Buenos Aires</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hernan Trimarchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Durand</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Canalis</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Fernandez</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Malvar</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Ramos Mejía</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristian Kramer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IPHIC</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derlis Gonzalez</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Paraguay</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 12, 2019</study_first_submitted>
  <study_first_submitted_qc>July 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2019</study_first_posted>
  <last_update_submitted>July 26, 2019</last_update_submitted>
  <last_update_submitted_qc>July 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>epoetin</keyword>
  <keyword>erythropoietin</keyword>
  <keyword>Eprex</keyword>
  <keyword>Hemax</keyword>
  <keyword>Anemia</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>pre-dialysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Anemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

